Recombinant Human CD38 Protein
- Known as:
- Recombinant Human CD38 Protein
- Catalog number:
- cd-785
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Proxinobio
- Gene target:
- Recombinant Human CD38 Protein
Related genes to: Recombinant Human CD38 Protein
- Gene:
- CD38 NIH gene
- Name:
- CD38 molecule
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4p15.32
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2014-11-18
Related products to: Recombinant Human CD38 Protein
Related articles to: Recombinant Human CD38 Protein
- Aging is a complex biological process uniquely shaped in women by hormonal transitions, particularly across the menopause transition. While chronological age alone fails to capture individual health variability, emerging molecular biomarkers offer tools to quantify biological aging and understand mechanisms underlying age-related decline. This review synthesizes the current landscape of aging biomarkers, including senescence-associated secretory phenotype factors, epigenetic clocks, clonal hematopoiesis of indeterminate potential, and telomere length, with a particular emphasis on their relevance to menopause. - Source: PubMed
Publication date: 2026/05/05
Castaneda ReginaUddenberg Erin RHurtado Andrade Maria DMeek Jesse LFrankhouser Kaylin NFaubion Stephanie SChini Eduardo NLeBrasseur Nathan KBrar Pamila KShufelt Chrisandra L - Emerging data show that B-cell depleting chemotherapies, which are increasingly used to treat autoimmune disorders and multiple sclerosis, can be associated with mucosal side effects such as inflammatory vaginitis. - Source: PubMed
Publication date: 2026/04/21
Bar OfriMurthy MeenaCosgrove KatherineSaidi YusraEl-Arar WafaeGoldenberg MilesSauvage GabrielBergerat AgnesCooley Demidkina BriahLaliberte KarenXu JiawuPierson GraceKwon Douglas SNiles JohnYassour MoranMitchell Caroline M - Management of patients with refractory or frequently relapsing (r/r) immune thrombotic thrombocytopenic purpura (iTTP) remains challenging, with no established consensus on optimal therapeutic strategies. In recent years, plasma-cell depletion with daratumumab, a monoclonal antibody against CD38, has been used successfully for treatment-resistant patients with various autoimmune diseases, including iTTP, although long-term data remain limited. - Source: PubMed
Publication date: 2026/03/04
Schimmer Romanvan den Berg JanaSchraner MarissaTrinchero AliceHolbro AndreasKremer Hovinga Johanna AStudt Jan-Dirk - The manipulation of host cellular metabolism is a key strategy for flaviviruses like Japanese encephalitis virus (JEV) to establish a productive infection. This study identifies the host NADase CD38 as a central regulator of this process. Using a CRISPR/Cas9-generated CD38 knockout (KO) TM3 cell model, we found that CD38 deficiency significantly restricted the production of infectious viral particles. While loss of CD38 also partially impaired viral entry, our central finding is that CD38 primarily promotes JEV infection by suppressing a host-intrinsic metabolic defense. We show that CD38 deficiency leads to a surge in intracellular NAD+, which sustains SIRT1 activity and inactivates p53, thereby blocking the mitochondrial apoptosis required for viral propagation. The dominance of this metabolic axis was confirmed through bidirectional pharmacological interventions; while SIRT1 inhibition using EX527 restored JEV replication, SIRT1 activation using SRT1720 suppressed it in wild-type cells. Our work reveals that JEV hijacks the CD38-NAD+-SIRT1-p53 axis to overcome host metabolic defenses in reproductive cell models, establishing CD38 as a promising therapeutic target. - Source: PubMed
Publication date: 2026/04/01
Yang YuanyuanZhang RuiqinLi XinranLiu XinleiDai YuGu YuLi JiahuiChen HaodongZheng YiWu Rui - Leukemic stem cells (LSCs) are the cellular reservoir most strongly implicated in relapse of acute myeloid leukemia, yet their operational detection by multiparameter flow cytometry remains challenging because of immunophenotypic overlap with normal progenitors and variability across assays. Including CD45RA in the CD34⁺CD38⁻ gating strategy substantially improves discrimination between malignant and normal stem/progenitor populations and thus enables more precise LSC enumeration in a single-tube format. Given the clinical importance of accurately quantifying the LSC compartment, we evaluated a refined single-tube flow cytometry assay that incorporates CD45RA within the CD34 + CD38- gate to increase specificity for the leukemic stem compartment. - Source: PubMed
Publication date: 2026/05/02
Navidinia Amir AbbasRostami ShahrbanooKarami NajibeShemshadinia MohammadrezaPatekhor Habibeh SabriHajaliaskari AkramMohammadi SaeedRostami TaherehBarkhordar MaryamVaezi MohammadJanbabaei GhasemChahardouli Bahram